raltegravir Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antivirals	2352	518048-05-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: MK0518 isentress raltegravir raltegravir potassium MK-0518	Raltegravir inhibits the catalytic activity of HIV-1 integrase, an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the covalent insertion, or integration, of unintegrated linear HIV-1 DNA into the host cell genome preventing the formation of the HIV-1 provirus. The provirus is required to direct the production of progeny virus, so inhibiting integration prevents propagation of the viral infection. Molecular weight: 444.42 Formula: C20H21FN6O5 CLOGP: 1.16 LIPINSKI: 1 HAC: 11 HDO: 3 TPSA: 150.02 ALOGS: -3.66 ROTB: 6 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

MK0518
isentress
raltegravir
raltegravir potassium
MK-0518

Raltegravir inhibits the catalytic activity of HIV-1 integrase, an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the covalent insertion, or integration, of unintegrated linear HIV-1 DNA into the host cell genome preventing the formation of the HIV-1 provirus. The provirus is required to direct the production of progeny virus, so inhibiting integration prevents propagation of the viral infection.

Molecular weight: 444.42
Formula: C20H21FN6O5
CLOGP: 1.16
LIPINSKI: 1
HAC: 11
HDO: 3
TPSA: 150.02
ALOGS: -3.66
ROTB: 6

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.80	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	9 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	25.72 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	31.80 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Dec. 20, 2007	EMA
Oct. 12, 2007	FDA	MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Exposure during pregnancy	1180.16	22.47	511	8102	107701	46569748
Foetal exposure during pregnancy	463.73	22.47	184	8429	30563	46646886
Maternal exposure during pregnancy	341.05	22.47	220	8393	102329	46575120
Abortion spontaneous	240.53	22.47	130	8483	43516	46633933
Virologic failure	180.05	22.47	47	8566	2008	46675441
Premature baby	174.56	22.47	79	8534	18033	46659416
Immune reconstitution inflammatory syndrome	167.59	22.47	56	8557	5669	46671780
Blood HIV RNULL increased	117.93	22.47	27	8586	660	46676789
Premature delivery	113.84	22.47	63	8550	22006	46655443
Drug reaction with eosinophilia and systemic symptoms	111.83	22.47	69	8544	29479	46647970
Premature labour	111.09	22.47	50	8563	11249	46666200
Lipodystrophy acquired	110.81	22.47	30	8583	1475	46675974
Pathogen resistance	104.30	22.47	40	8573	6020	46671429
Caesarean section	98.46	22.47	52	8561	16551	46660898
Live birth	96.14	22.47	44	8569	10286	46667163
Ectopic kidney	86.63	22.47	15	8598	78	46677371
Viral mutation identified	86.37	22.47	26	8587	1873	46675576
Sudden infant death syndrome	84.65	22.47	17	8596	217	46677232
Foetal growth restriction	84.00	22.47	35	8578	6532	46670917
Abortion induced	80.97	22.47	39	8574	10221	46667228
Viral load increased	80.95	22.47	23	8590	1352	46676097
Treatment noncompliance	79.74	22.47	56	8557	29675	46647774
Hepatocellular injury	66.42	22.47	50	8563	29472	46647977
Congenital heart valve disorder	65.76	22.47	12	8601	88	46677361
Neonatal respiratory arrest	63.56	22.47	11	8602	57	46677392
Gastroschisis	62.35	22.47	13	8600	202	46677247
Cloacal exstrophy	61.99	22.47	12	8601	125	46677324
Drug resistance	61.74	22.47	39	8574	17329	46660120
Congenital pulmonary valve disorder	56.98	22.47	10	8603	57	46677392
Congenital genital malformation	56.96	22.47	11	8602	113	46677336
Bladder agenesis	56.53	22.47	11	8602	118	46677331
Genitalia external ambiguous	55.40	22.47	11	8602	132	46677317
Immune reconstitution inflammatory syndrome associated tuberculosis	54.61	22.47	13	8600	378	46677071
Complication of delivery	54.44	22.47	11	8602	145	46677304
Foetal death	53.57	22.47	28	8585	8715	46668734
Meconium stain	53.31	22.47	11	8602	162	46677287
Gastrointestinal disorder congenital	52.40	22.47	10	8603	96	46677353
Meningomyelocele	51.53	22.47	13	8600	483	46676966
Premature rupture of membranes	51.32	22.47	22	8591	4401	46673048
Tethered cord syndrome	50.82	22.47	11	8602	206	46677243
Hemivertebra	50.75	22.47	10	8603	115	46677334
Caudal regression syndrome	49.91	22.47	10	8603	126	46677323
Anal atresia	49.82	22.47	12	8601	367	46677082
Maternal drugs affecting foetus	49.75	22.47	23	8590	5495	46671954
CD4 lymphocytes decreased	48.10	22.47	16	8597	1594	46675855
Generalised anxiety disorder	47.62	22.47	16	8597	1644	46675805
Pulmonary valve sclerosis	46.63	22.47	8	8605	39	46677410
Drug ineffective	45.96	22.47	35	8578	677803	45999646
Cardiac murmur	44.05	22.47	27	8586	11377	46666072
Spine malformation	43.76	22.47	10	8603	242	46677207
Hyperbilirubinaemia	43.63	22.47	26	8587	10412	46667037
Stillbirth	43.26	22.47	22	8591	6469	46670980
Gastrointestinal malformation	42.92	22.47	9	8604	144	46677305
Congenital choroid plexus cyst	42.10	22.47	10	8603	288	46677161
Renal tubular dysfunction	41.90	22.47	10	8603	294	46677155
Cholestasis of pregnancy	41.01	22.47	13	8600	1111	46676338
Exomphalos	40.87	22.47	11	8602	528	46676921
Umbilical cord abnormality	39.67	22.47	11	8602	591	46676858
Pre-eclampsia	38.96	22.47	22	8591	7972	46669477
Fall	38.76	22.47	7	8606	329090	46348359
Gestational diabetes	38.27	22.47	21	8592	7198	46670251
Low birth weight baby	37.92	22.47	19	8594	5415	46672034
Congenital anomaly	36.74	22.47	13	8600	1559	46675890
Hepatitis fulminant	36.46	22.47	16	8597	3386	46674063
Drug interaction	34.88	22.47	99	8514	202995	46474454
Pain	34.38	22.47	23	8590	476925	46200524
Product size issue	34.20	22.47	9	8604	396	46677053
Viral load decreased	34.07	22.47	6	8607	35	46677414
Large for dates baby	33.01	22.47	9	8604	454	46676995
Ventricular hypertrophy	31.61	22.47	15	8598	3799	46673650
Nephropathy toxic	29.68	22.47	18	8595	7436	46670013
Anaemia	29.67	22.47	109	8504	255670	46421779
Microcephaly	29.48	22.47	9	8604	679	46676770
Eosinophilia	29.38	22.47	26	8587	19191	46658258
Thymus hypoplasia	28.87	22.47	5	8608	26	46677423
Mental disability	27.84	22.47	6	8607	110	46677339
Oesophageal candidiasis	27.21	22.47	15	8598	5185	46672264
Genotype drug resistance test positive	27.05	22.47	8	8605	542	46676907
Mitochondrial cytopathy	26.80	22.47	7	8606	299	46677150
Diastasis recti abdominis	26.49	22.47	5	8608	45	46677404
Rash maculo-papular	26.34	22.47	29	8584	27845	46649604
Small for dates baby	26.21	22.47	13	8600	3624	46673825
Antiviral drug level below therapeutic	25.92	22.47	5	8608	51	46677398
Cholestasis	25.45	22.47	28	8585	26865	46650584
Chronic papillomatous dermatitis	25.18	22.47	5	8608	60	46677389
Congenital ectopic bladder	24.81	22.47	5	8608	65	46677384
Amniotic cavity infection	24.73	22.47	9	8604	1169	46676280
Anencephaly	24.71	22.47	6	8607	190	46677259
Neural tube defect	24.59	22.47	6	8607	194	46677255
Acute stress disorder	24.10	22.47	6	8607	211	46677238
Fatigue	23.74	22.47	48	8565	608649	46068800
Hepatotoxicity	23.60	22.47	26	8587	24983	46652466
Pregnancy	23.53	22.47	27	8586	27110	46650339
Dermatitis exfoliative	23.27	22.47	14	8599	5702	46671747
Pulmonary tuberculosis	22.99	22.47	13	8600	4718	46672731
Bronchopulmonary dysplasia	22.69	22.47	6	8607	269	46677180
Hemiataxia	22.61	22.47	4	8609	24	46677425
Aqueductal stenosis	22.61	22.47	4	8609	24	46677425
Patent ductus arteriosus	22.61	22.47	12	8601	3850	46673599

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	463.91	14.11	566	16437	199002	29736473
Depression	415.13	14.11	370	16633	90067	29845408
Immune reconstitution inflammatory syndrome	361.06	14.11	150	16853	8951	29926524
Lipodystrophy acquired	344.08	14.11	113	16890	3447	29932028
Virologic failure	334.72	14.11	108	16895	3111	29932364
Foetal exposure during pregnancy	282.41	14.11	204	16799	36667	29898808
Pathogen resistance	259.22	14.11	116	16887	8294	29927181
Mitochondrial toxicity	243.72	14.11	80	16923	2434	29933041
Progressive external ophthalmoplegia	224.15	14.11	64	16939	1202	29934273
Eyelid ptosis	197.25	14.11	83	16920	5105	29930370
Viral mutation identified	181.99	14.11	65	16938	2561	29932914
Blood HIV RNULL increased	165.70	14.11	52	16951	1364	29934111
Drug resistance	144.02	14.11	107	16896	20026	29915449
Viral load increased	126.61	14.11	51	16952	2803	29932672
Renal tubular disorder	102.07	14.11	52	16951	4954	29930521
Diplopia	100.27	14.11	74	16929	13698	29921777
Gene mutation	87.17	14.11	28	16975	793	29934682
Volvulus	78.86	14.11	29	16974	1242	29934233
Drug reaction with eosinophilia and systemic symptoms	77.40	14.11	88	16915	28400	29907075
Brachydactyly	75.80	14.11	18	16985	156	29935319
Osteoporotic fracture	69.19	14.11	25	16978	1018	29934457
CD4 lymphocytes decreased	68.40	14.11	30	16973	2040	29933435
HIV infection	64.43	14.11	27	16976	1641	29933834
Depression suicidal	60.75	14.11	24	16979	1252	29934223
Loss of personal independence in daily activities	59.30	14.11	67	16936	21468	29914007
Extraocular muscle paresis	58.35	14.11	18	16985	445	29935030
Ophthalmoplegia	56.79	14.11	23	16980	1281	29934194
Psychiatric decompensation	56.60	14.11	23	16980	1292	29934183
Hepatitis C	56.27	14.11	52	16951	13153	29922322
HIV-associated neurocognitive disorder	54.84	14.11	16	16987	325	29935150
Treatment failure	53.37	14.11	81	16922	34598	29900877
CSF HIV escape syndrome	50.03	14.11	12	16991	109	29935366
Cytomegalovirus chorioretinitis	49.87	14.11	28	16975	3240	29932235
Oesophageal candidiasis	48.31	14.11	30	16973	4180	29931295
Genital herpes	47.42	14.11	16	16987	530	29934945
Tearfulness	45.93	14.11	21	16982	1575	29933900
Oesophageal atresia	45.59	14.11	15	16988	459	29935016
Hemivertebra	45.37	14.11	11	16992	105	29935370
Gastrointestinal tube insertion	43.73	14.11	19	16984	1262	29934213
Osteoporosis	43.52	14.11	41	16962	10622	29924853
Laryngomalacia	40.40	14.11	12	16991	260	29935215
Drug level decreased	39.58	14.11	30	16973	5775	29929700
Paranoia	39.35	14.11	38	16965	10150	29925325
Genital herpes simplex	38.57	14.11	10	16993	128	29935347
Renal impairment	37.51	14.11	119	16884	84065	29851410
Low birth weight baby	36.21	14.11	29	16974	6047	29929428
Anogenital dysplasia	35.72	14.11	10	16993	174	29935301
Completed suicide	34.94	14.11	7	16996	99485	29835990
Anal cancer	34.72	14.11	12	16991	428	29935047
Genotype drug resistance test positive	33.83	14.11	17	16986	1572	29933903
Superior mesenteric artery syndrome	33.42	14.11	8	16995	72	29935403
Premature baby	33.07	14.11	44	16959	16647	29918828
Congenital mitral valve incompetence	32.75	14.11	8	16995	79	29935396
Blood creatine phosphokinase increased	31.59	14.11	74	16929	43774	29891701
Atrial fibrillation	31.54	14.11	11	16992	108113	29827362
Hepatic cirrhosis	31.43	14.11	42	16961	15957	29919518
Dyslipidaemia	31.32	14.11	26	16977	5701	29929774
HIV lipodystrophy	30.30	14.11	6	16997	19	29935456
Suicidal ideation	29.42	14.11	64	16939	36050	29899425
Drug abuse	28.34	14.11	6	16997	82066	29853409
Spine malformation	28.17	14.11	8	16995	147	29935328
Congenital skin dimples	27.97	14.11	8	16995	151	29935324
HIV associated nephropathy	27.78	14.11	9	16994	262	29935213
Pneumonia	27.26	14.11	98	16905	334208	29601267
Dyspnoea	26.98	14.11	98	16905	333197	29602278
Fanconi syndrome acquired	26.73	14.11	16	16987	2087	29933388
Adverse event	26.72	14.11	38	16965	15303	29920172
Intestinal malrotation	26.65	14.11	6	16997	40	29935435
Hypotension	26.30	14.11	46	16957	200519	29734956
Nephrolithiasis	26.21	14.11	49	16954	24761	29910714
Drug level increased	25.61	14.11	41	16962	18313	29917162
Hepatic enzyme decreased	24.77	14.11	6	16997	57	29935418
Enanthema	24.28	14.11	9	16994	394	29935081
Nephropathy toxic	24.14	14.11	30	16973	10609	29924866
Confusional state	23.65	14.11	25	16978	134809	29800666
Cholestasis	23.57	14.11	47	16956	24903	29910572
Hyperlipidaemia	23.56	14.11	34	16969	13873	29921602
Disease progression	23.51	14.11	8	16995	79866	29855609
Haemophilic arthropathy	23.38	14.11	7	16996	156	29935319
Congenital vesicoureteric reflux	23.11	14.11	5	16998	27	29935448
Mycobacterium avium complex infection	23.01	14.11	16	16987	2695	29932780
Oesophageal carcinoma	22.84	14.11	17	16986	3184	29932291
Dysphagia	22.41	14.11	77	16926	56621	29878854
Depressive symptom	22.17	14.11	13	16990	1632	29933843
Acquired immunodeficiency syndrome	22.16	14.11	9	16994	505	29934970
Lymphoma	22.11	14.11	28	16975	10093	29925382
Hypertriglyceridaemia	21.95	14.11	25	16978	8073	29927402
Fall	21.82	14.11	44	16959	181828	29753647
Back pain	21.62	14.11	16	16987	102580	29832895
Hyperbilirubinaemia	21.16	14.11	36	16967	16906	29918569
Osteonecrosis	21.10	14.11	35	16968	16100	29919375
Treatment noncompliance	20.84	14.11	45	16958	25208	29910267
Acquired gene mutation	20.63	14.11	11	16992	1150	29934325
Jaundice	20.38	14.11	52	16951	32434	29903041
Hemiparaesthesia	20.32	14.11	5	16998	51	29935424
Cardiac arrest	20.19	14.11	14	16989	92836	29842639
VACTERL syndrome	20.12	14.11	4	16999	13	29935462
Antiviral drug level above therapeutic	19.98	14.11	5	16998	55	29935420
Heart transplant rejection	19.84	14.11	11	16992	1242	29934233
Myopathy	19.59	14.11	27	16976	10559	29924916
Congenital ureteric anomaly	19.47	14.11	4	16999	16	29935459
Hyperphagia	19.19	14.11	11	16992	1324	29934151
Chronic hepatitis C	19.00	14.11	8	16995	492	29934983
Cachexia	18.92	14.11	21	16982	6590	29928885
Congenital renal disorder	18.68	14.11	5	16998	73	29935402
Acute hepatitis C	18.64	14.11	6	16997	171	29935304
Lipohypertrophy	18.62	14.11	7	16996	319	29935156
Pulmonary tuberculosis	18.54	14.11	18	16985	4839	29930636
Respiratory failure	18.39	14.11	18	16985	100624	29834851
Cerebral ventricle dilatation	18.31	14.11	9	16994	793	29934682
Infection	18.02	14.11	11	16992	78063	29857412
Choroiditis	17.97	14.11	9	16994	826	29934649
Cardiomyopathy acute	17.72	14.11	4	16999	27	29935448
Lymphocytic infiltration	17.70	14.11	8	16995	584	29934891
Drug-induced liver injury	17.66	14.11	38	16965	21236	29914239
Intensive care unit acquired weakness	17.60	14.11	9	16994	863	29934612
Hepatitis cholestatic	17.55	14.11	22	16981	7850	29927625
Syphilis	17.52	14.11	7	16996	376	29935099
Tracheal fistula repair	17.35	14.11	3	17000	3	29935472
Rash maculo-papular	17.33	14.11	42	16961	25376	29910099
Meningitis cryptococcal	17.31	14.11	12	16991	2012	29933463
Retinal toxicity	17.24	14.11	7	16996	392	29935083
Vertigo	17.17	14.11	39	16964	22596	29912879
Toxicity to various agents	17.15	14.11	48	16955	177135	29758340
Pancreatitis acute	17.03	14.11	42	16961	25653	29909822
Abnormal dreams	17.01	14.11	22	16981	8093	29927382
Hepatic failure	16.88	14.11	50	16953	33993	29901482
Seborrhoeic dermatitis	16.86	14.11	10	16993	1283	29934192
Glycosuria	16.73	14.11	10	16993	1301	29934174
Congenital hydronephrosis	16.67	14.11	8	16995	669	29934806
Myelocytosis	16.61	14.11	4	16999	37	29935438
Constipation	16.57	14.11	24	16979	112882	29822593
Renal failure	16.25	14.11	127	16876	128839	29806636
Liver disorder	16.04	14.11	45	16958	29677	29905798
Erosive duodenitis	16.04	14.11	10	16993	1403	29934072
Nephrocalcinosis	15.98	14.11	7	16996	474	29935001
Insomnia	15.94	14.11	99	16904	93237	29842238
Lymphogranuloma venereum	15.82	14.11	3	17000	7	29935468
Fat tissue decreased	15.74	14.11	4	16999	47	29935428
Hepatotoxicity	15.74	14.11	33	16970	18112	29917363
Kidney enlargement	15.60	14.11	8	16995	772	29934703
Malignant neoplasm progression	15.58	14.11	11	16992	72276	29863199
Birth trauma	15.53	14.11	3	17000	8	29935467
Atypical mycobacterial infection	15.43	14.11	8	16995	790	29934685
Tracheal deviation	15.27	14.11	3	17000	9	29935466
Psychomotor skills impaired	15.22	14.11	11	16992	1968	29933507
Hepatitis B	15.21	14.11	18	16985	6054	29929421
Alopecia areata	15.20	14.11	5	16998	153	29935322
Subacute combined cord degeneration	15.20	14.11	5	16998	153	29935322
Hepatorenal syndrome	14.99	14.11	12	16991	2499	29932976
Induration	14.90	14.11	8	16995	848	29934627
Cardio-respiratory arrest	14.80	14.11	7	16996	57299	29878176
Proteinuria	14.75	14.11	30	16973	16115	29919360
Pneumocystis jirovecii pneumonia	14.69	14.11	31	16972	17089	29918386
Cardiac failure congestive	14.40	14.11	16	16987	84391	29851084
Congenital syphilis	14.23	14.11	3	17000	14	29935461
Intervertebral discitis	14.20	14.11	10	16993	1719	29933756
Adrenal suppression	14.15	14.11	7	16996	626	29934849

Pharmacologic Action:

Source	Code	Description
ATC	J05AJ01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Integrase inhibitors
ATC	J05AR16	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations
FDA MoA	N0000000127	HIV Integrase Inhibitors
MeSH PA	D019380	Anti-HIV Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D044966	Anti-Retroviral Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D019428	HIV Integrase Inhibitors
MeSH PA	D019429	Integrase Inhibitors
FDA EPC	N0000175887	Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
CHEBI has role	CHEBI:36044	anti-virus drug

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Human immunodeficiency virus infection	indication	86406008	DOID:526
Disorder of muscle	contraindication	129565002	DOID:423
Rhabdomyolysis	contraindication	240131006
Breastfeeding (mother)	contraindication	413712001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.19	acidic
pKa2	10.89	acidic
pKa3	12.18	acidic
pKa4	2.3	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 400MG BASE	ISENTRESS	MERCK SHARP DOHME	N022145	Oct. 12, 2007	RX	TABLET	ORAL	May 22, 2021	PEDIATRIC EXCLUSIVITY
EQ 600MG BASE	ISENTRESS HD	MERCK SHARP DOHME	N022145	May 26, 2017	RX	TABLET	ORAL	May 22, 2021	PEDIATRIC EXCLUSIVITY
EQ 100MG BASE	ISENTRESS	MERCK SHARP DOHME	N203045	Dec. 21, 2011	RX	TABLET, CHEWABLE	ORAL	May 22, 2021	PEDIATRIC EXCLUSIVITY
EQ 25MG BASE	ISENTRESS	MERCK SHARP DOHME	N203045	Dec. 21, 2011	RX	TABLET, CHEWABLE	ORAL	May 22, 2021	PEDIATRIC EXCLUSIVITY
EQ 100MG BASE/PACKET	ISENTRESS	MERCK SHARP DOHME	N205786	Dec. 20, 2013	RX	POWDER	ORAL	May 22, 2021	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
C-C chemokine receptor type 1	GPCR	P32246	CCR1_HUMAN		Ki	8.30	CHEMBL
Integrase	Enzyme		Q7ZJM1_9HIV1	INHIBITOR	IC50	8	CHEMBL	CHEMBL
Gag-Pol polyprotein	Polyprotein		POL_HV1BR	INHIBITOR	IC50	7.52	WOMBAT-PK
Integrase	Enzyme		Q76353_9HIV1		IC50	5.74	CHEMBL

External reference:

ID	Source
D06676	KEGG_DRUG
871038-72-1	SECONDARY_CAS_RN
4026736	VANDF
C1966407	UMLSCUI
CHEBI:82960	CHEBI
RLT	PDB_CHEM_ID
CHEMBL254316	ChEMBL_ID
CHEMBL518520	ChEMBL_ID
D000068898	MESH_DESCRIPTOR_UI
DB06817	DRUGBANK_ID
11571	IUPHAR_LIGAND_ID
8842	INN_ID
22VKV8053U	UNII
23668479	PUBCHEM_CID
1235585	RXNORM
121359	MMSL
24597	MMSL
31069	MMSL
d07048	MMSL
012364	NDDF
012365	NDDF
429368003	SNOMEDCT_US
429707008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0227	TABLET, FILM COATED	400 mg	ORAL	NDA	31 sections
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0473	TABLET, CHEWABLE	25 mg	ORAL	NDA	31 sections
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0477	TABLET, CHEWABLE	100 mg	ORAL	NDA	31 sections
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3080	TABLET, FILM COATED	600 mg	ORAL	NDA	31 sections
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	0006-3603	GRANULE, FOR SUSPENSION	100 mg	ORAL	NDA	31 sections
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1085	TABLET, FILM COATED	400 mg	ORAL	NDA	30 sections
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0650	TABLET, FILM COATED	400 mg	ORAL	NDA	28 sections
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	54868-0117	TABLET, FILM COATED	400 mg	ORAL	NDA	30 sections
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	61919-706	TABLET, FILM COATED	400 mg	ORAL	NDA	15 sections
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	61919-706	TABLET, FILM COATED	400 mg	ORAL	NDA	15 sections
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	66336-214	TABLET, FILM COATED	400 mg	ORAL	NDA	30 sections
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	67296-1235	TABLET, FILM COATED	400 mg	ORAL	NDA	18 sections
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	68071-2113	TABLET, FILM COATED	400 mg	ORAL	NDA	29 sections
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	70518-1621	TABLET, FILM COATED	400 mg	ORAL	NDA	30 sections
ISENTRESS	HUMAN PRESCRIPTION DRUG LABEL	1	76519-1130	TABLET, FILM COATED	400 mg	ORAL	NDA	17 sections